BEAUFORT, S.C.--(BUSINESS WIRE)--This analysis investigates CLI patients, who despite a successful procedure, do not respond to endovascular and surgical revascularization. This group is termed Non-Responders.
“CLI Non-Responders represent an important and costly group of patients,” stated Mary L. Yost, President of THE SAGE GROUP. “Consequences include unhealed or delayed healing of ulcers and wounds, frequent repeat revascularizations and major amputation. These adversely affect patient quality of life, as well as add significantly to healthcare costs.”
Describing the research Ms. Yost explained, “We identified and analyzed numerous risk factors associated with non-response to revascularization, ultimately focusing on seven candidates. These were the risk-factors that we believed had the best ability to predict non-response to revascularization and to calculate the number of U.S. CLI patients in the Non-Responder category.”
“Significantly, the risk factors shared many common characteristics including microvascular disease, foot artery disease and diabetic foot ulcers (DFU),” added Ms. Yost.
“CLI Non-Responders are not the same population as the “No-Option” patients. However, there is likely some overlap between the two,” Yost clarified.
“Based on our research, we believe there are several significant unmet needs in CLI diagnosis and treatment,” Yost concluded. “These include new treatment technologies to address this sizeable patient group and new non-invasive technologies to measure skin perfusion during and after revascularization in CLI patients.”
CLI, or ‘end-stage’ peripheral artery disease (PAD), is characterized by rest pain, ulcers and gangrene.
About the Report: Critical Limb Ischemia (CLI) Non-Responders: Patients Who Do Not Respond To Revascularization, Factors That Identify Non-Response And Non-Responder Prevalence And Markets
The report contains a comprehensive analysis of the potential risk factors associated with CLI Non-Responders. Seven risk factors are identified and analyzed with regard to their ability to predict non-response and to calculate the number of U.S. CLI patients in the Non-Responder category. Prevalence of CLI Non-Responders and the market is calculated for each of the seven risk factors for 2015-2030.
Additional information: http://thesagegroup.us/pages/reports/cli-non-responders.php
THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease, specifically chronic venous disease (CVD), PAD, CLI, DFU and the costs and consequences of amputation.
Additional information: www.thesagegroup.us.